July 2018; 5 (4) Clinical/Scientific NotesOpen Access
Obinutuzumab, a potent anti–B-cell agent, for rituximab-unresponsive IgM anti-MAG neuropathy
Goran Rakocevic, Ubaldo Martinez-Outschoorn, Marinos C. Dalakas
First published April 5, 2018, DOI: https://doi.org/10.1212/NXI.0000000000000460
Goran Rakocevic
From the Department of Neurology (G.R., M.C.D.), Department of Hematology (U.M.-O.), Thomas Jefferson University, Philadelphia, PA; and Neuroimmunology Unit (M.C.D.), Department of Pathophysiology, Faculty of Medicine, National and Kapodistrian University of Athens, Greece.
Ubaldo Martinez-Outschoorn
From the Department of Neurology (G.R., M.C.D.), Department of Hematology (U.M.-O.), Thomas Jefferson University, Philadelphia, PA; and Neuroimmunology Unit (M.C.D.), Department of Pathophysiology, Faculty of Medicine, National and Kapodistrian University of Athens, Greece.
Marinos C. Dalakas
From the Department of Neurology (G.R., M.C.D.), Department of Hematology (U.M.-O.), Thomas Jefferson University, Philadelphia, PA; and Neuroimmunology Unit (M.C.D.), Department of Pathophysiology, Faculty of Medicine, National and Kapodistrian University of Athens, Greece.
Obinutuzumab, a potent anti–B-cell agent, for rituximab-unresponsive IgM anti-MAG neuropathy
Goran Rakocevic, Ubaldo Martinez-Outschoorn, Marinos C. Dalakas
Neurol Neuroimmunol Neuroinflamm Jul 2018, 5 (4) e460; DOI: 10.1212/NXI.0000000000000460
Citation Manager Formats
Make Comment
See Comments

Article Figures & Data
Tables
Letters: Rapid online correspondence
- Author Response: Obinutuzumab, a potent anti–B-cell agent, for rituximab-unresponsive IgM anti-MAG neuropathy
- Marinos C. Dalakas, Professor of Neurology, Thomas Jefferson University Philadelphia, PA and National and Kapodistrian University of Athens Medical School, Athens Greece
- Ubaldo Martinez-Outschoorn, Associate Professor, Thomas Jefferson University Philadelphia, PA
- Goran Rakocevic, Associate Professor, Thomas Jefferson University Philadelphia, PA
Submitted May 04, 2018 - RE: Obinutuzumab, a new anti-CD20 antibody, is active and effective in anti-MAG antibody polyneuropathy.
- Chiara Briani, Neurologist, Department of Neurosciences, University of Padova, Italy
- Andrea Visentin, Hematologist, Hematology Unit, Department of Medicine, University of Padova, Italy
- Alessandro Salvalaggio, Neurology resident, Department of Neurosciences, University of Padova, Italy
- Mario Cacciavillani, Neurophysiologist, CEMES, Data-Medica Group, Padova
- Livio Trentin, Hematologist, Hematology Unit, Department of Medicine, University of Padova, Italy
Submitted April 16, 2018
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Advertisement
Dr. David E. Vaillancourt and Dr. Shannon Y. Chiu
► Watch
Related Articles
- No related articles found.
Topics Discussed
Alert Me
Recommended articles
-
Views & Reviews
Targeting B Cells to Modify MS, NMOSD, and MOGADPart 1Jonas Graf, Jan Mares, Michael Barnett et al.Neurology: Neuroimmunology & Neuroinflammation, December 16, 2020 -
Clinical/Scientific Notes
LONG-TERM EFFECT OF RITUXIMAB IN ANTI-MAG POLYNEUROPATHYL. Benedetti, C. Briani, D. Franciotta et al.Neurology, November 17, 2008 -
Article
The Bruton tyrosine kinase inhibitor ibrutinib improves anti-MAG antibody polyneuropathyFrancesca Castellani, Andrea Visentin, Marta Campagnolo et al.Neurology: Neuroimmunology & Neuroinflammation, April 13, 2020 -
Views & Reviews
The Wide Spectrum of Pathophysiologic Mechanisms of Paraproteinemic NeuropathyJean-Michel Vallat, Mathilde Duchesne, Philippe Corcia et al.Neurology, December 04, 2020